{"DataElement":{"publicId":"4614115","version":"1","preferredName":"Stage I Stage II Stage IIIA Stage IIIB Disease Progression Platinum-Based Chemotherapy Date","preferredDefinition":"The date of progression of Stage I-IIIB disease following a regimen of platinum-based chemotherapy.","longName":"4614114v1.0:2018550v1.0","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"4614114","version":"1","preferredName":"Stage I Stage II Stage IIIA Stage IIIB Disease Progression Platinum-Based Chemotherapy","preferredDefinition":"Progression of Stage I-IIIB disease following a regimen of platinum-based chemotherapy","longName":"4614111v1.0:4614112v1.0","context":"SWOG","contextVersion":"1","ObjectClass":{"publicId":"4614111","version":"1","preferredName":"Stage I Stage II Stage IIIA Stage IIIB Disease Progression","preferredDefinition":"Invasive cancer confined to the original anatomic site of growth without lymph node involvement.:Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.:Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites. The definition of stage IIIA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIA is defined as follows: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. T3: Tumor more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIA is defined as follows: T3a, N0, M0. T3a: Tumor involves lower third of vagina, no extension to pelvic wall. N0: No regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.):Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.  The definition of stage IIIB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIB is defined as follows: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules). N0: No regional lymph node metastasis. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axilla","longName":"4614111v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I","conceptCode":"C27966","definition":"Invasive cancer confined to the original anatomic site of growth without lymph node involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Stage II","conceptCode":"C28054","definition":"Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Stage IIIA","conceptCode":"C27977","definition":"Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites. The definition of stage IIIA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIA is defined as follows: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. T3: Tumor more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIA is defined as follows: T3a, N0, M0. T3a: Tumor involves lower third of vagina, no extension to pelvic wall. N0: No regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage IIIB","conceptCode":"C27978","definition":"Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.  The definition of stage IIIB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIB is defined as follows: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules). N0: No regional lymph node metastasis. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIB is defined as follows: (T3b, Any N, M0); (T1-3, N1, M0). T3: Tumor extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or non-functioning kidney. T3b: Tumor extends to pelvic wall and/or causes hydronephrosis or non-functioning kidney. N1: Regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08BE25B1-BDF6-050B-E050-BB89AD4301A0","latestVersionIndicator":"Yes","beginDate":"2014-11-26","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-11-26","modifiedBy":"ONEDATA","dateModified":"2014-11-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4614112","version":"1","preferredName":"Platinum-Based Chemotherapy","preferredDefinition":"Derived from or containing platinum.:The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term is used to describe any therapy involving the use of chemical-based agents, it is particularly used to refer to the use of chemical-based agents to treat cancer. Antineoplastic chemotherapy works by arresting or killing the growth and spread of cancer cells. Chemotherapy may also include agents that enhance immune function or alter hormonal activity.","longName":"C25620:C15632","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Platinum-Based","conceptCode":"C25620","definition":"Derived from or containing platinum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08BE25B1-BE04-050B-E050-BB89AD4301A0","latestVersionIndicator":"Yes","beginDate":"2014-11-26","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-11-26","modifiedBy":"ONEDATA","dateModified":"2014-11-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08BE25B1-BE15-050B-E050-BB89AD4301A0","latestVersionIndicator":"Yes","beginDate":"2014-11-26","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-11-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018550","version":"1","preferredName":"Date","preferredDefinition":"The date on which an observation was made or an event occurred.","longName":"DT","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"DATE","minLength":null,"maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"format":"MM/DD/YYYY","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2233081","version":"1","preferredName":"Date","preferredDefinition":"a particular day specified as the time something has, or will, happen.","longName":"C25164","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F90B5E56-BB15-0F45-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-09","modifiedBy":"ONEDATA","dateModified":"2005-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"B54EF112-5457-674A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-28","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-28","modifiedBy":"ZHWENDY","dateModified":"2023-12-12","changeDescription":"8/3/17 tt added Diagnosis CSI. 6/20/17 jk transferred to NCI Standards per confirmation by Brian Campbell as part of Round 5 finalization task, added reg status.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811953","version":"1","longName":"Disease Description","context":"CTEP"},{"publicId":"2811962","version":"1","longName":"Response","context":"CTEP"},{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Date of progression following","type":"Preferred Question Text","description":"Date of progression following this regimen","url":null,"context":"SWOG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08BE25B1-BE26-050B-E050-BB89AD4301A0","latestVersionIndicator":"Yes","beginDate":"2014-11-26","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-11-26","modifiedBy":"KEARNSD","dateModified":"2014-11-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}